dabrafenib Clinical Research Trials | TrialX

Loading...

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Age Group

Any (1)

Phase 1 (1)

Interventional (1)

JS InnoPharm, LLC (1)

No (1)

No (1)

Adult (18+) (1)

I am/have/had

I am/have/hadmeasurable disease

I am/have/hadcancer

I am/have/hadneutrophil count

I am/have/hadmetastasis

I am/have/hadmetastatic melanoma

I am/have/hadgilbert's syndrome

I am/have/hadserum pregnancy test

I am/have/hadsolid neoplasm

I am/have/hadlung cancer

I am/have/hadbrain metastasis

I am/have/hadliver metastasis

I am/have/hadmetastatic malignant solid neoplasm

I am/have/hadalt/ast

I am/have/hadnon-small cell lung cancer

I am/have/hadstage iv nsclc

I am/have/hadinvestigational treatment

I am/have/hadbraf v600e mutation

I am/have/hadbrain metastases

I am/have/hadadjuvant therapy

I am/have/hadmetastatic malignant solid tumor

added new label for I am/have/had

more

I am looking for

I am looking fordabrafenib

I am looking formelanoma

I am looking formek inhibitor

I am looking foradjuvant

I am looking foripilimumab

I am looking forras-gap

I am looking forras-gef

I am looking forimmunomodulators

I am looking forimmunomodulator

added new label for I am looking for

more

Advanced Filters

Loading...

Found 1 clinical trials

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

Phase 1
For Seniors
For adults
Recruiting in 100s
Interventional Study
all
Recruiting

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

This is a Phase 1 study of JSI-1187 as monotherapy and in combination with dabrafenib for the treatment of advanced solid tumors with MAPK pathway mutations, including mutations that cause MAPK pathway hyperactivation.

stage iv nsclc

investigational treatment

non-small cell lung cancer

solid neoplasm

ras-gef

0 views
19 Feb, 2024
4 locations

Congrats! You have your own personal workspace now.

Learn more

© Copyright TrialX 2025 All rights reserved.